RESUMEN
Altered activity of specific enzymes in phenylalanine-tyrosine (phe-tyr) metabolism results in incomplete breakdown of various metabolite substrates in this pathway. Increased biofluid concentration and tissue accumulation of the phe-tyr pathway metabolite homogentisic acid (HGA) is central to pathophysiology in the inherited disorder alkaptonuria (AKU). Accumulation of metabolites upstream of HGA, including tyrosine, occurs in patients on nitisinone, a licenced drug for AKU and hereditary tyrosinaemia type 1, which inhibits the enzyme responsible for HGA production. The aim of this study was to investigate the phe-tyr metabolite content of key biofluids and tissues in AKU mice on and off nitisinone to gain new insights into the biodistribution of metabolites in these altered metabolic states. The data show for the first time that HGA is present in bile in AKU (mean [±SD] = 1003[±410] µmol/L; nitisinone-treated AKU mean [±SD] = 45[±23] µmol/L). Biliary tyrosine, 3(4-hydroxyphenyl)pyruvic acid (HPPA) and 3(4-hydroxyphenyl)lactic acid (HPLA) are also increased on nitisinone. Urine was confirmed as the dominant elimination route of HGA in untreated AKU, but with indication of biliary excretion. These data provide new insights into pathways of phe-tyr metabolite biodistribution and metabolism, showing for the first time that hepatobiliary excretion contributes to the total pool of metabolites in this pathway. Our data suggest that biliary elimination of organic acids and other metabolites may play an underappreciated role in disorders of metabolism. We propose that our finding of approximately 3.8 times greater urinary HGA excretion in AKU mice compared with patients is one reason for the lack of extensive tissue ochronosis in the AKU mouse model.
Asunto(s)
Alcaptonuria , Ciclohexanonas , Modelos Animales de Enfermedad , Ácido Homogentísico , Nitrobenzoatos , Alcaptonuria/orina , Alcaptonuria/metabolismo , Animales , Ácido Homogentísico/orina , Ácido Homogentísico/metabolismo , Ratones , Ciclohexanonas/orina , Masculino , Tirosina/metabolismo , Tirosina/orina , Hígado/metabolismo , Fenilalanina/metabolismoRESUMEN
INTRODUCTION: The design of training programs for football players is not straightforward due to intra- and inter-individual variability that leads to different physiological responses under similar training loads. OBJECTIVE: To study the association between the external load, defined by variables obtained using electronic performance tracking systems (EPTS), and the urinary metabolome as a surrogate of the metabolic adaptation to training. METHODS: Urine metabolic and EPTS data from 80 professional football players collected in an observational longitudinal study were analyzed by ultra-performance liquid chromatography coupled to electrospray ionization quadrupole time-of-flight mass spectrometry and assessed by partial least squares (PLS) regression. RESULTS: PLS models identified steroid hormone metabolites, hypoxanthine metabolites, acetylated amino acids, intermediates in phenylalanine metabolism, tyrosine, tryptophan metabolites, and riboflavin among the most relevant variables associated with external load. Metabolic network analysis identified enriched pathways including steroid hormone biosynthesis and metabolism of tyrosine and tryptophan. The ratio of players showing a deviation from the PLS model of adaptation to exercise was higher among those who suffered a muscular lesion compared to those who did not. CONCLUSIONS: There was a significant association between the external load and the urinary metabolic profile, with alteration of biochemical pathways associated with long-term adaptation to training. Future studies should focus on the validation of these findings and the development of metabolic models to identify professional football players at risk of developing muscular injuries.
Asunto(s)
Metabolómica , Fútbol , Adolescente , Aminoácidos/metabolismo , Aminoácidos/orina , Hormonas Esteroides Gonadales/metabolismo , Hormonas Esteroides Gonadales/orina , Humanos , Hipoxantina/metabolismo , Hipoxantina/orina , Análisis de los Mínimos Cuadrados , Masculino , Fenilalanina/metabolismo , Fenilalanina/orina , Riboflavina/metabolismo , Riboflavina/orina , Triptófano/metabolismo , Triptófano/orina , Tirosina/metabolismo , Tirosina/orina , Adulto JovenRESUMEN
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a distinct eosinophilic phenotype of severe asthma with accompanying chronic rhinosinusitis, nasal polyposis, and hypersensitivity to aspirin. Urinary 3-bromotyrosine (uBrTyr) is a noninvasive marker of eosinophil-catalyzed protein oxidation. The lack of in vitro diagnostic test makes the diagnosis of AERD difficult. We aimed to determine uBrTyr levels in patients with AERD (n = 240) and aspirin-tolerant asthma (ATA) (n = 226) and to assess whether its addition to urinary leukotriene E4 (uLTE4) levels and blood eosinophilia can improve the prediction of AERD diagnosis. METHODS: Clinical data, spirometry and blood eosinophilis were evaluated. UBrTyr and uLTE4 levels were measured in urine by HPLC and ELISA, respectively. RESULTS: Both groups of asthmatics (AERD, n = 240; ATA, n = 226) had significantly higher uBrTyr, uLTE4 levels, and blood eosinophils than healthy controls (HC) (n = 71) (p < 0.05). ULTE4 levels and blood eosinophils were significantly higher in AERD as compared to ATA (p = 0.004, p < 0.0001, respectively). whereas uBrTyr levels were not significantly different between both asthma phenotypes (p = 0.34). Asthmatics with high levels of uBrTyr (> 0.101 ng/mg Cr), uLTE4 levels (> 800 pg/mg Cr) and blood eosinophils (> 300 cells/ul) were 7 times more likely to have AERD.. However, uBrTyr did not increase the benefit for predicting AERD when uLTE4 and blood eosinophils were already taken into account (p = 0.57). CONCLUSION: UBrTyr levels are elevated both in AERD and ATA as compared to HC, but they could not differentiate between these asthma phenotypes suggesting a similar eosinophilic activation. The addition of uBrTyr to elevated uLTE4 levels and blood eosinophils did not statistically enhance the prediction of AERD diagnosis.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Aspirina/efectos adversos , Asma Inducida por Aspirina/diagnóstico , Asma Inducida por Aspirina/orina , Tirosina/análogos & derivados , Adulto , Asma Inducida por Aspirina/sangre , Biomarcadores/orina , Eosinófilos/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tirosina/orinaRESUMEN
Here, we aimed to use graphene oxide to improve the selectivity and sensitivity of Tyr determination via the reaction with 1-nitroso-2-naphthol as a selective reagent of Tyr. The reaction between Tyr and 1-nitroso-2-naphthol in absence and presence of GO was studied spectrophotometrically. Different parameters such as concentrations, temperature, incubation time were optimized. The obtained data showed that the maximum absorbance was achieved by using 2â¯mL of 0.03% 1-nitroso-2-naphthol at temperature 60⯰C for 10â¯min. On the basis of calibration curve of various concentrations of Tyr in the presence of 20⯵gâ¯mL-1 GO, the limit of detection was 6.4â¯×â¯10-6â¯M (1.15⯵gâ¯mL-1), where in absence of GO was 1.1â¯×â¯10-5â¯M (19.9⯵gâ¯mL-1). The selectivity of Tyr in presence of other amino acids and phenols was studied with and without GO. The data obtained revealed that the selectivity of Tyr in presence of GO with respect to some amino acids and phenols was improved. The proposed method has been applied for the determination of Tyr in urine and serum samples. Therefore, GO is a powerful catalytic surface for the sensitive and selective determination of Try in biological fluids.
Asunto(s)
Grafito/química , Nanoestructuras/química , Tirosina/análisis , Aminoácidos/química , Líquidos Corporales/química , Humanos , Límite de Detección , Microscopía Electrónica de Rastreo , Fenoles/química , Espectroscopía Infrarroja por Transformada de Fourier , Tirosina/sangre , Tirosina/orinaRESUMEN
BACKGROUND: Routine prenatal care fails to identify a large proportion of women at risk of fetal growth restriction (FGR). Metabolomics, the comprehensive analysis of low molecular weight molecules (metabolites) in biological samples, can provide new and earlier biomarkers of prenatal health. Recent research has suggested possible predictive first trimester urine metabolites correlating to fetal growth restriction in the third trimester. Our objective in this current study was to examine urinary metabolic profiles in the first and second trimester of pregnancy in relation to third trimester FGR in a US population from a large, multi-center cohort study of healthy pregnant women. METHODS: We conducted a nested case-control study within The Infant Development and the Environment Study (TIDES), a population-based multi-center pregnancy cohort study. We identified 53 cases of FGR based on the AUDIPOG [Neonatal growth - AUDIPOG [Internet]. [cited 29 Nov 2016]. Available from: http://www.audipog.net/courbes_morpho.php?langue=en ] formula for birthweight percentile considering maternal height, age, and prenatal weight, as well as infant sex, gestational age, and birth rank. Cases were matched to 106 controls based on study site, maternal age (± 2 years), parity, and infant sex. NMR spectroscopy was used to assess concentrations of four urinary metabolites that have been previously associated with FGR (tyrosine, acetate, formate, and trimethylamine) in first and second trimester urine samples. We fit multivariate conditional logistic regression models to estimate the odds of FGR in relation to urinary concentrations of these individual metabolites in the first and second trimesters. Exploratory analyses of custom binned spectroscopy results were run to consider other potentially related metabolites. RESULTS: We found no significant association between the relative concentrations of each of the four metabolites and odds of FGR. Exploratory analyses did not reveal any significant differences in urinary metabolic profiles. Compared with controls, cases delivered earlier (38.6 vs 39.8, p < 0.001), and had lower birthweights (2527 g vs 3471 g, p < 0.001). Maternal BMI was similar between cases and controls. CONCLUSIONS: First and second trimester concentrations of urinary metabolites (acetate, formate, trimethylamine and tyrosine) did not predict FGR. This inconsistency with previous studies highlights the need for more rigorous investigation and data collection in this area before metabolomics can be clinically applied to obstetrics.
Asunto(s)
Retardo del Crecimiento Fetal/etiología , Primer Trimestre del Embarazo/orina , Segundo Trimestre del Embarazo/orina , Orina/química , Acetatos/orina , Adulto , Estudios de Casos y Controles , Femenino , Formiatos/orina , Edad Gestacional , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Modelos Logísticos , Edad Materna , Metaboloma , Metilaminas/orina , Análisis Multivariante , Oportunidad Relativa , Embarazo , Medición de Riesgo , Factores de Riesgo , Tirosina/orina , Estados UnidosRESUMEN
This study described an automated online method for the simultaneous determination of 8-isoprostane, 8-hydroxy-2'-deoxyguanosine, and 3-nitro-l-tyrosine in human urine. The method involves in-tube solid-phase microextraction using a Carboxen 1006 PLOT capillary column as an extraction device, followed by liquid chromatography with tandem mass spectrometry using a CX column and detection in the negative/positive switching ion-mode by multiple reaction monitoring. Using their stable isotope-labeled internal standards, each of these oxidative stress biomarkers showed good linearity from 0.02 to 2.0 ng/mL. Their detection limits (S/N = 3) were 3.4-21.5 pg/mL, and their intra- and inter-day precisions (relative standard deviations) were >3.9 and 6.5% (n = 5), respectively. This method was applied successfully to the analysis of urine samples, without any other pretreatment and interference peaks.
Asunto(s)
Cromatografía Liquida/métodos , Desoxiguanosina/análogos & derivados , Dinoprost/análogos & derivados , Estrés Oxidativo , Microextracción en Fase Sólida/métodos , Espectrometría de Masas en Tándem/métodos , Tirosina/análogos & derivados , 8-Hidroxi-2'-Desoxicoguanosina , Biomarcadores/orina , Desoxiguanosina/aislamiento & purificación , Desoxiguanosina/orina , Dinoprost/aislamiento & purificación , Dinoprost/orina , Humanos , Límite de Detección , Masculino , Espectrometría de Masa por Ionización de Electrospray , Tirosina/aislamiento & purificación , Tirosina/orinaRESUMEN
BACKGROUND: Casein and whey proteins differ in amino acid composition and absorption rate; however, the absorption rate of casein can be increased to mimic that of whey proteins by exogenous hydrolysis. In view of these compositional differences, we studied the metabolic responses to intake of casein, hydrolyzed casein, and whey proteins in overweight and moderately obese men and women by investigating select urinary and blood plasma metabolites. RESULTS: A total of 21 urinary and 23 plasma metabolites were identified by nuclear magnetic resonance spectroscopy. The postprandial plasma metabolites revealed a significant diet-time interaction for isoleucine (P = 0.001) and tyrosine (P = 0.001). The level of isoleucine and tyrosine peaked 90 min postprandially with a 1.4-fold difference following intake of whey proteins compared with either casein or hydrolyzed casein. A 1.2-fold higher urinary level of lactate was observed after intake of whey proteins compared with intake of intact casein (P < 0.01). CONCLUSION: The plasma metabolites revealed different amino acid profiles reflecting the amino acid composition of casein and whey proteins. Furthermore, the results support that casein hydrolysates neither affect the postprandial amino acid absorption rate nor the amino acid level compared with that of intact casein. The urinary lactate increases following whey protein intake might indicate a higher metabolism of glucogenic amino acids. © 2018 Society of Chemical Industry.
Asunto(s)
Caseínas/química , Obesidad/dietoterapia , Sobrepeso/dietoterapia , Proteína de Suero de Leche/metabolismo , Adulto , Caseínas/metabolismo , Femenino , Humanos , Isoleucina/sangre , Isoleucina/orina , Masculino , Obesidad/sangre , Obesidad/orina , Sobrepeso/sangre , Sobrepeso/orina , Plasma/química , Periodo Posprandial , Tirosina/sangre , Tirosina/orina , Orina/química , Adulto JovenRESUMEN
Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism due to the deficient activity of N-acetylgalactosamine-6-sulfate sulfatase that leads to accumulation of the keratan sulfate and chondroitin 6-sulfate in body fluids and in lysosomes. The pathophysiology of this lysosomal storage disorder is not completely understood. The aim of this study was to investigate oxidative stress parameters, pro-inflammatory cytokine and GAG levels in MPS IVA patients. We analyzed urine and blood samples from patients under ERT (n=17) and healthy age-matched controls (n=10-15). Patients presented a reduction of antioxidant defense levels, assessed by a decrease in glutathione content and by an increase in superoxide dismutase activity in erythrocytes. Concerning lipid and protein damage, it was verified increased urine isoprostanes and di-tyrosine levels and decreased plasma sulfhydryl groups in MPS IVA patients compared to controls. MPS IVA patients showed higher DNA damage than control group and this damage had an oxidative origin in both pyrimidine and purine bases. Interleukin 6 was increased in patients and presented an inverse correlation with GSH levels, showing a possible link between inflammation and oxidative stress in MPS IVA disease. The data presented suggest that pro-inflammatory and pro-oxidant states occur in MPS IVA patients even under ERT. Taking these results into account, supplementation of antioxidants in combination with ERT can be a tentative therapeutic approach with the purpose of improving the patient's quality of life. To the best of our knowledge, this is the first study relating MPS IVA patients with oxidative stress.
Asunto(s)
Condroitinsulfatasas/uso terapéutico , Terapia de Reemplazo Enzimático/métodos , Inflamación/tratamiento farmacológico , Mucopolisacaridosis IV/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , 8-Hidroxi-2'-Desoxicoguanosina , Adolescente , Adulto , Proteínas Sanguíneas/análisis , Niño , Creatinina/orina , Citocinas/sangre , Desoxiguanosina/análogos & derivados , Desoxiguanosina/orina , Eritrocitos/efectos de los fármacos , Eritrocitos/metabolismo , Femenino , Glutatión/sangre , Glicosaminoglicanos/orina , Humanos , Inflamación/sangre , Inflamación/orina , Isoprostanos/orina , Masculino , Mucopolisacaridosis IV/sangre , Mucopolisacaridosis IV/orina , Peroxidasa/sangre , Superóxido Dismutasa/sangre , Resultado del Tratamiento , Tirosina/análogos & derivados , Tirosina/orina , Adulto JovenRESUMEN
BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic disease that requires long-term medical management and monitoring. The eosinophil count determined during esophageal biopsy remains the gold standard for diagnosis and monitoring of EoE. Although markers of eosinophil degranulation correlate with symptoms, eosinophil counts do not correlate. Development of a noninvasive, cost-effective biomarker of eosinophil activation for the evaluation of EoE is an unmet medical need. OBJECTIVE: To conduct a proof-of-concept study to evaluate the potential for measuring urinary 3-bromotyrosine (3-BT) levels in creatinine normalized urine for quantifying eosinophil degranulation in EoE disease. METHODS: A mass spectrometry-based method of measuring normalized 3-BT levels, the Eosinophil Quantitated Urine Kinetic (EoQUIK), was developed, and proof-of-concept evaluation was performed for patients with EoE (n = 27), atopic controls (n = 24), and nonatopic controls (n = 24). RESULTS: EoQUIK revealed that median normalized 3-BT levels were increased 93-fold in patients with EoE compared with nonatopic controls (P = .01) and increased 13-fold in patients with EoE compared with atopic controls (P = .01). Cutoff thresholds were selected for EoQUIK that yielded a specificity of 100% and a negative predictive value of 100% for nonatopic controls and a specificity of 79% and a negative predictive value of 90% for atopic controls. In a logistic regression model, a urine 3-BT level greater than 20 pg per 400 mg of creatinine increased the odds of a patient having EoE by 4.8 (95% confidence interval, 1.14-20.5; P = .03) when compared with atopic controls after controlling for race and sex. CONCLUSION: These data provide proof of concept that EoQUIK can potentially be a useful noninvasive clinical tool in the evaluation of possible EoE.
Asunto(s)
Esofagitis Eosinofílica/orina , Tirosina/análogos & derivados , Adolescente , Adulto , Bioensayo , Niño , Preescolar , Esofagitis Eosinofílica/diagnóstico , Esofagitis Eosinofílica/inmunología , Eosinófilos/inmunología , Femenino , Humanos , Recuento de Leucocitos , Masculino , Tirosina/orina , Adulto JovenRESUMEN
BACKGROUND: Asthma is a heterogeneous disease with different phenotypes. Inhaled corticosteroid (ICS) therapy is a mainstay of treatment for asthma, but the clinical response to ICSs is variable. OBJECTIVE: We hypothesized that a panel of inflammatory biomarkers (ie, fraction of exhaled nitric oxide [Feno], sputum eosinophil count, and urinary bromotyrosine [BrTyr] level) might predict steroid responsiveness. METHODS: The original study from which this analysis originates comprised 2 phases: a steroid-naive phase 1 and a 28-day trial of ICSs (phase 2) during which Feno values, sputum eosinophil counts, and urinary BrTyr levels were measured. The response to ICSs was based on clinical improvements, including a 12% or greater increase in FEV1, a 0.5-point or greater decrease in Asthma Control Questionnaire score, and 2 doubling dose or greater increase in provocative concentration of adenosine 5'-monophosphate causing a 20% decrease in FEV1 (PC20AMP). Healthy control subjects were also evaluated in this study for comparison of biomarkers with those seen in asthmatic patients. RESULTS: Asthmatic patients had higher than normal Feno values, sputum eosinophil counts, and urinary BrTyr levels during the steroid-naive phase and after ICS therapy. After 28-day trial of ICSs, Feno values decreased in 82% of asthmatic patients, sputum eosinophil counts decreased in 60%, and urinary BrTyr levels decreased in 58%. Each of the biomarkers at the steroid-naive phase had utility for predicting steroid responsiveness, but the combination of high Feno values and high urinary BrTyr levels had the best power (13.3-fold, P < .01) to predict a favorable response to ICS therapy. However, the magnitude of the decrease in biomarker levels was unrelated to the magnitude of clinical response to ICS therapy. CONCLUSION: A noninvasive panel of biomarkers in steroid-naive asthmatic patients predicts clinical responsiveness to ICS therapy.
Asunto(s)
Corticoesteroides/uso terapéutico , Asma/diagnóstico , Asma/tratamiento farmacológico , Fenotipo , Administración por Inhalación , Corticoesteroides/administración & dosificación , Adulto , Asma/etiología , Biomarcadores , Estudios de Casos y Controles , Espiración , Femenino , Humanos , Recuento de Leucocitos , Masculino , Óxido Nítrico , Oportunidad Relativa , Pronóstico , Pruebas de Función Respiratoria , Resultado del Tratamiento , Tirosina/análogos & derivados , Tirosina/orinaRESUMEN
Metabolic profiling of biofluids from tuberculosis (TB) patients would help us in understanding the disease pathophysiology and may also be useful for the development of novel diagnostics and host-directed therapy. In this pilot study we have compared the urine metabolic profiles of two groups of subjects having similar TB symptoms and categorized as active TB (ATB, n = 21) and non-TB (NTB, n = 21) based on GeneXpert test results. Silylation, gas chromatography mass spectrometry, and standard chemometric methods were employed to identify the important molecules and deregulated metabolic pathways. Eleven active TB patients were followed up on longitudinally for comparative urine metabolic profiling with healthy controls (n = 11). A set of 42 features qualified to have a variable importance parameter score of > 1.5 of a partial least-squares discriminate analysis model and fold change of > 1.5 at p value < 0.05 between ATB and NTB. Using these variables, a receiver operating characteristics curve was plotted and the area under the curve was calculated to be 0.85 (95% CI: 0.72-0.96). Several of these variables that represent norepinephrine, gentisic acid, 4-hydroxybenzoic acid, hydroquinone, and 4-hydroxyhippuric acid are part of the tyrosine-phenylalanine metabolic pathway. In the longitudinal study we observed a treatment-dependent trend in the urine metabolome of follow-up samples, and subjects declared as clinically cured showed similar metabolic profile as those of asymptomatic healthy subjects. The deregulated tyrosine-phenylalanine axis reveals a potential target for diagnostics and intervention in TB.
Asunto(s)
Biomarcadores/metabolismo , Redes y Vías Metabólicas/fisiología , Metaboloma/fisiología , Fenilalanina/metabolismo , Tuberculosis Pulmonar/fisiopatología , Tirosina/metabolismo , Análisis Discriminante , Cromatografía de Gases y Espectrometría de Masas , Humanos , Estudios Longitudinales , Fenilalanina/orina , Proyectos Piloto , Curva ROC , Tuberculosis Pulmonar/metabolismo , Tirosina/orinaRESUMEN
Reactive nitrogen species (RNS) can modify proteins at tyrosine and tryptophan residues, and they are involved in the pathogenesis of various human diseases. In this study, we present the first liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based method that enables the simultaneous measurement of urinary 3-nitrotyrosine (3-NTYR) and its metabolite 3-nitro-4-hydroxyphenylacetic acid (NHPA). After the addition of stable isotope-labeled internal standards, urine samples were purified and enriched using manual solid-phase extraction (SPE) and HPLC fractionation followed by online SPE LC-MS/MS analysis. The limits of quantification in urine were 3.1 and 2.5 pg/mL for 3-NTYR and NHPA, respectively. Inter- and intraday imprecision was <15%. The mean relative recoveries of 3-NTYR and NHPA in urine were 89-98% and 90-98%, respectively. We further applied this method to 65 urinary samples from healthy subjects. Urinary samples were also analyzed for N-nitrosodimethylamine (NDMA) as well as oxidative and methylated DNA lesions, namely, 8-oxo-7,8-dihydroguanine (8-oxoGua), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo), N7-methylguanine (N7-MeG), and N3-methyladenine (N3-MeA), using reported LC-MS/MS methods. Urinary 3-NTYR and NHPA levels were measured at concentrations of 63.2 ± 51.5 and 77.4 ± 60.8 pg/mL, respectively. Urinary 3-NTYR and NHPA levels were highly correlated with each other and with 8-oxoGua and 8-oxodGuo. Our findings demonstrated that a relationship exists between oxidative and nitrative stress. However, 3-NTYR and NHPA were correlated with N7-MeG and N3-MeA but not with NDMA, suggesting that NDMA may not be a representative biomarker of N-nitroso compounds that are induced by RNS.
Asunto(s)
Metilación de ADN , Nitrofenoles/orina , Fenilacetatos/orina , Tirosina/análogos & derivados , 8-Hidroxi-2'-Desoxicoguanosina , Adenina/análogos & derivados , Adenina/orina , Adulto , Cromatografía Líquida de Alta Presión , Cromatografía Liquida , Desoxiguanosina/análogos & derivados , Desoxiguanosina/orina , Dimetilnitrosamina/orina , Guanina/análogos & derivados , Guanina/orina , Humanos , Límite de Detección , Persona de Mediana Edad , Oxidación-Reducción , Extracción en Fase Sólida , Espectrometría de Masas en Tándem , Tirosina/orina , Adulto JovenRESUMEN
We developed and validated a simple and fast UFLC-MS/MS method for the accurate determination of 3-nitrotyrosine (3-NT) in human urine as a noninvasive biomarker for oxidative stress. The method, involving tailored 96-well µElution solid-phase extraction (SPE) combined with UFLC-MS/MS, allows 3-NT to be determined in biological samples without the need for hydrolysis, derivatization, evaporation, and two-dimensional LC for the first time. Using ammonium acetate (pH 9, 25 mM) as an elution buffer was found to improve SPE selectivity. Fast chromatographic elution of 3-NT with a total run time of 7 min was achieved on a PFPP column (150 mm × 2.1 mm, 3 µm). This fine-tuned integrated method delivered significantly improved throughput, specificity, and sensitivity while reducing the matrix effect, solvent usage, and waste disposal. Using this simple and rapid method, two plates of urine samples (n = 192) can be processed within 24 h. The lower limit of quantification for 3-NT is 10 pg/mL, which represents a notable sensitivity enhancement over reported methods. Less than 6.0 % variations for intraday and interday assay precisions and 97.7-106.3% for accuracies in terms of recovery were obtained. The applicability and reliability of the method were demonstrated by determining the reference range in human urine for 82 healthy people. Considering the noninvasive and inexpensive nature of urine sampling, this novel method could be used to re-evaluate the role of 3-NT as an oxidative stress biomarker in pre-clinical and clinical studies.
Asunto(s)
Extracción en Fase Sólida/métodos , Espectrometría de Masas en Tándem/métodos , Tirosina/análogos & derivados , Biomarcadores/orina , Cromatografía Liquida/métodos , Humanos , Límite de Detección , Reproducibilidad de los Resultados , Tirosina/orinaRESUMEN
Major depressive disorder (MDD) is a prevalent and debilitating mental disorder. Yet, there are no objective biomarkers available to support diagnostic laboratory testing for this disease. Here, gas chromatography-mass spectrometry was applied to urine metabolic profiling of 126 MDD and 134 control subjects. Orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to identify the differential metabolites in MDD subjects relative to healthy controls. The OPLS-DA analysis of data from training samples (82 first-episode, drug-naïve MDD subjects and 82 well-matched healthy controls) showed that the depressed group was significantly distinguishable from the control group. Totally, 23 differential urinary metabolites responsible for the discrimination between the two groups were identified. Postanalysis, 6 of the 23 metabolites (sorbitol, uric acid, azelaic acid, quinolinic acid, hippuric acid, and tyrosine) were defined as candidate diagnostic biomarkers for MDD. Receiver operating characteristic analysis of combined levels of these six biomarkers yielded an area under the receiver operating characteristic curve (AUC) of 0.905 in distinguishing training samples; this simplified metabolite signature classified blinded test samples (44 MDD subjects and 52 healthy controls) with an AUC of 0.837. Furthermore, a composite panel by the addition of previously identified urine biomarker (N-methylnicotinamide) to this biomarker panel achieved a more satisfactory accuracy, yielding an AUC of 0.909 in the training samples and 0.917 in the test samples. Taken together, these results suggest this composite urinary metabolite signature should facilitate development of a urine-based diagnostic test for MDD.
Asunto(s)
Trastorno Depresivo Mayor , Metaboloma , Adulto , Biomarcadores/orina , Estudios de Casos y Controles , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/orina , Ácidos Dicarboxílicos/orina , Análisis Discriminante , Femenino , Cromatografía de Gases y Espectrometría de Masas , Hipuratos/orina , Humanos , Análisis de los Mínimos Cuadrados , Masculino , Persona de Mediana Edad , Niacinamida/análogos & derivados , Niacinamida/orina , Ácido Quinolínico/orina , Curva ROC , Sorbitol/orina , Tirosina/orina , Ácido Úrico/orinaRESUMEN
We report citrin deficiency in a neonatal non-East-Asian patient, the ninth Caucasian reported with this disease. The association of intrahepatic cholestasis, galactosuria, very high alpha-fetoprotein and increased plasma and urine citrulline, tyrosine, methionine and threonine levels suggested citrin deficiency. Identification of a protein-truncating mutation (c.1078C>T; p.Arg360*) in the SLC25A13 gene confirmed the diagnosis. An immediate response to a high-protein, lactose-free, low-carbohydrate formula was observed. Our report illustrates the need for awareness on citrin deficiency in Western countries.
Asunto(s)
Proteínas de Unión al Calcio/deficiencia , Proteínas de Unión al Calcio/genética , Dietoterapia , Proteínas de Transporte de Membrana Mitocondrial/genética , Transportadores de Anión Orgánico/deficiencia , Transportadores de Anión Orgánico/genética , Pueblo Asiatico/genética , Proteínas de Unión al Calcio/sangre , Proteínas de Unión al Calcio/orina , Citrulina/sangre , Citrulina/orina , Humanos , Metionina/sangre , Metionina/orina , Mutación , Transportadores de Anión Orgánico/sangre , Transportadores de Anión Orgánico/orina , Rumanía , España , Treonina/sangre , Treonina/orina , Tirosina/sangre , Tirosina/orina , Población Blanca/genéticaRESUMEN
OBJECTIVE: To investigate whether lipid and protein oxidation products are elevated and correlated with routine clinical markers of hepatic and renal function in patients anesthetized with halothane, isoflurane, or sevoflurane. METHODS: Urine and blood samples were collected from patient groups. Excretion of aldehydes, acetone, and o,o'-dityrosine was measured before and after anesthesia. Blood samples were analysed for clinical markers. RESULTS: Urinary concentrations of aldehydes, acetone, o,o'-dityrosine and glucose were significantly increased after anesthesia in halothane and sevoflurane groups earlier than clinical markers. Significant correlations were found in sevoflurane group. CONCLUSION: Lipid and protein oxidation contributes to subclinical sevoflurane nephrotoxicity. Oxidation products may serve as early biomarkers.
Asunto(s)
Anestésicos por Inhalación/efectos adversos , Biomarcadores/orina , Halotano/efectos adversos , Isoflurano/efectos adversos , Enfermedades Renales/inducido químicamente , Riñón/efectos de los fármacos , Lípidos/orina , Éteres Metílicos/efectos adversos , Proteinuria/etiología , Acetona/orina , Aldehídos/orina , Femenino , Glucosuria/etiología , Humanos , Masculino , Oxidación-Reducción , Sevoflurano , Tirosina/análogos & derivados , Tirosina/orinaRESUMEN
A rapid, highly sensitive, and selective method was applied in a non-invasive way to investigate the antidepressant action of Xiaoyaosan (XYS) using ultra performance liquid chromatography-mass spectrometry (UPLC-MS) and chemometrics. Many significantly altered metabolites were used to explain the mechanism. Venlafaxine HCl and fluoxetine HCl were used as chemical positive control drugs with a relatively clear mechanism of action to evaluate the efficiency and to predict the mechanism of action of XYS. Urine obtained from rats subjected to chronic unpredictable mild stress (CUMS) was analyzed by UPLC-MS. Distinct changes in the pattern of metabolites in the rat urine after CUMS production and drug intervention were observed using partial least squares-discriminant analysis. The results of behavioral tests and multivariate analysis showed that CUMS was successfully reproduced, and a moderate-dose XYS produced significant therapeutic effects in the rodent model, equivalent to those of the positive control drugs, venlafaxine HCl and fluoxetine HCl. Metabolites with significant changes induced by CUMS were identified, and 17 biomarker candidates for stress and drug intervention were identified. The therapeutic effect of XYS on depression may involve regulation of the dysfunctions of energy metabolism, amino acid metabolism, and gut microflora changes. Metabonomic methods are valuable tools for measuring efficacy and mechanisms of action in the study of traditional Chinese medicines.
Asunto(s)
Antidepresivos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Tracto Gastrointestinal/microbiología , Redes y Vías Metabólicas/efectos de los fármacos , Microbiota/efectos de los fármacos , Fitoterapia , Animales , Antidepresivos/orina , Benzoatos/orina , Biomarcadores/orina , Hidrocarburos Aromáticos con Puentes/orina , Catequina/orina , Chalcona/análogos & derivados , Chalcona/orina , Cromatografía Liquida , Ácido Cítrico/orina , Ciclo del Ácido Cítrico/efectos de los fármacos , Ácidos Cumáricos/orina , Creatina Quinasa/efectos de los fármacos , Creatina Quinasa/orina , Creatinina/orina , Ciclohexanoles/uso terapéutico , Medicamentos Herbarios Chinos/análisis , Flavanonas/orina , Fluoxetina/uso terapéutico , Ácido Gálico/orina , Glucósidos/orina , Glicina/análogos & derivados , Glicina/efectos de los fármacos , Glicina/orina , Hipuratos/orina , Ácidos Cetoglutáricos/orina , Ácido Quinurénico/orina , Masculino , Espectrometría de Masas , Metabolómica , Monoterpenos , Extractos Vegetales/uso terapéutico , Ratas , Ratas Sprague-Dawley , Estrés Psicológico/tratamiento farmacológico , Triptófano/efectos de los fármacos , Triptófano/orina , Tirosina/efectos de los fármacos , Tirosina/orina , Clorhidrato de VenlafaxinaRESUMEN
Alkaptonuria (AKU) is an ultra-rare inherited inborn error of metabolism that afflicts the tyrosine metabolic pathway, resulting in the accumulation of homogentisic acid (HGA) in the circulation, and significant excretion in urine. Clinical manifestations, typically observed from the third decade of life, are lifelong and significantly affect the quality of life. This review provides a comprehensive overview of the natural history of AKU, including clinical, biochemical and genetic perspectives. An update on the major advances on studies in murine models and human subjects, providing mechanistic insight into the molecular and biochemical processes that underlie pathophysiology and its response to treatment are presented. The impact of treatment with nitisinone is also presented with a specific emphasis on hypertyrosinemia, as uncertainty on this topic remains. Future perspectives are explored, such as novel approaches to treat hypertyrosinemia including the use of binding agents and amino acid transporter inhibitors, as well as advanced potentially curative gene and cell therapy initiatives.
Asunto(s)
Alcaptonuria , Tirosinemias , Humanos , Animales , Ratones , Alcaptonuria/diagnóstico , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/metabolismo , Calidad de Vida , Ácido Homogentísico/metabolismo , Tirosina/metabolismo , Tirosina/orinaRESUMEN
Propionic (PA) and methylmalonic (MMA) acidurias are inherited disorders caused by deficiency of propionyl-CoA carboxylase and methylmalonyl-CoA mutase, respectively. Affected patients present acute metabolic crises in the neonatal period and long-term neurological deficits. Treatments of these diseases include a protein restricted diet and L: -carnitine supplementation. L: -Carnitine is widely used in the therapy of these diseases to prevent secondary L: -carnitine deficiency and promote detoxification, and several recent in vitro and in vivo studies have reported antioxidant and antiperoxidative effects of this compound. In this study, we evaluated the oxidative stress parameters, isoprostane and di-tyrosine levels, and the antioxidant capacity, in urine from patients with PA and MMA at the diagnosis, and during treatment with L: -carnitine and protein-restricted diet. We verified a significant increase of isoprostanes and di-tyrosine, as well as a significant reduction of the antioxidant capacity in urine from these patients at diagnosis, as compared to controls. Furthermore, treated patients presented a marked reduction of isoprostanes and di-tyrosine levels in relation to untreated patients. In addition, patients with higher levels of protein and lipid oxidative damage, determined by di-tyrosine and isoprostanes levels, also presented lower urinary concentrations of total and free L: -carnitine. In conclusion, the present results indicate that treatment with low protein diet and L: -carnitine significantly reduces urinary biomarkers of protein and lipid oxidative damage in patients with disorders of propionate metabolism and that L: -carnitine supplementation may be specially involved in this protection.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/dietoterapia , Errores Innatos del Metabolismo de los Aminoácidos/orina , Carnitina/uso terapéutico , Estrés Oxidativo/fisiología , Propionatos/metabolismo , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Antioxidantes/análisis , Antioxidantes/metabolismo , Carnitina/administración & dosificación , Carnitina/análisis , Carnitina/orina , Niño , Preescolar , Dieta con Restricción de Proteínas , Suplementos Dietéticos , Humanos , Lactante , Recién Nacido , Análisis por Apareamiento , Ácido Metilmalónico/metabolismo , Ácido Metilmalónico/orina , Estrés Oxidativo/efectos de los fármacos , Propionatos/orina , Resultado del Tratamiento , Tirosina/análisis , Tirosina/orinaRESUMEN
Reactive-nitrogen species, such as peroxynitrite (ONOO(-)) and nitryl chloride (NO(2)Cl), react with the aromatic ring of tyrosine in soluble amino acids and in proteins to form 3-nitrotyrosine. The extent of nitration can be quantified by measuring 3-nitrotyrosine in biological matrices, such as blood, urine, and tissue. This article reviews and discusses current analytical methodologies for the quantitative determination of 3-nitrotyrosine in their soluble and protein-associated forms, with the special focus being on free 3-nitrotyrosine. Special emphasis is given to analytical approaches based on the tandem mass spectrometry methodology. Pitfalls and solutions to overcome current methodological problems are emphasized and requirements for quantitative analytical approaches are recommended. The reliability of current analytical methods and the suitability of 3-nitrotyrosine as a biomarker of nitrative stress are thoroughly examined.